What's behind Moderna's latest 8.0% stock surge?

Traders Union
All News
Stocks
Moderna surges 8.02% today to $147.58

Highlights

The FDA approved Moderna's XFG-adapted Spikevax and mNexspike COVID-19 vaccines for 2026-2027, enabling immediate US distribution.
Moderna and Merck announced positive Phase 3 results for their personalized mRNA melanoma vaccine, showing a significant reduction in recurrence risk.
Moderna stock is in a strong uptrend above key support at $147.29, with a projected 5-day range of $137.1 to $155.72 and 75% probability of further upside.

Regulatory wins and trial results boost sentiment for infectious disease and oncology

The FDA approved Moderna's XFG-adapted Spikevax and mNexspike formulas for the 2026-2027 COVID-19 season, authorizing immediate US distribution. Additionally, Moderna and Merck & Co. announced positive Phase 3 trial results for their personalized mRNA melanoma vaccine developed with Keytruda, which showed significant reduction in melanoma recurrence risk. The intismeran cancer vaccine, which leverages similar mRNA technology to COVID-19 vaccines, is also being evaluated for lung, kidney, and bladder cancers. These developments demonstrate ongoing progress in both infectious disease prevention and cancer immunotherapies.

Anton Kharitonov, expert at Traders Union, sees the Moderna surge as potentially overextended, powered by headline-driven enthusiasm. He notes that the bullish breakout is not fully confirmed given intraday volatility and momentum-oscillator divergences. Kharitonov remains cautious about sustainability, especially as market sentiment could swiftly reverse if expectations fail to play out. He warns that prices hovering at resistance near $149.56 combined with oversold Stochastic RSI signals elevate pullback risks. "The market is too quick to price in positive news, so I would guard against chasing momentum at these levels," says Kharitonov.

Viktoras Karapetjanc, expert at Traders Union, believes Moderna’s new FDA approvals and positive results with Merck reinforce strong upside potential. He sees institutional confidence growing as the cancer vaccine platform broadens to multiple indications. Karapetjanc notes the bullish structure remains intact above all key moving averages, supported by robust technical signals. "Further growth is expected if price clears $149.56 — the market offers multiple setups for momentum traders," Karapetjanc states.

Sholanke Dele, market strategist, questions the durability of Moderna's recent gains amid ongoing high intraday volatility. Dele views the strong rally as potentially vulnerable if there is any disappointment around clinical progress or distribution. He points to a mild divergence between momentum and oscillators as a warning signal. "Investors should stay vigilant — sharp reversals are likely if bullish momentum fades," warns Dele.

Sustained bullish trend as technical indicators diverge with oscillators

Moderna trades above its 20-day ($129.45), 50-day ($89.63), and 200-day ($56.54) moving averages, confirming sustained bullish momentum across all timeframes. Immediate resistance is set near $149.56, with support at $147.29, marking recent range highs. Momentum remains strong as shown by MACD (Strong Buy) and ADX (Buy) signals, while the RSI at 58.5 also reads Buy. The Stochastic RSI indicates oversold conditions at 2.62, CCI is neutral, and Bull/Bear Power is positive at 0.78, indicating buyers dominate. Intraday volatility is elevated at 10.78%, with the price near session highs and firm intraday tone, though a mild divergence appears between bullish momentum indicators and oversold oscillators.

Earlier, analysts noted that Moderna's stock was overheated following a sharp rally, with volatility driven by both technical factors and a series of high-impact corporate events. With new FDA approvals and positive clinical data supporting further gains, traders should watch for a confirmed breakout above $149.56 or a reversal below $147.29 to signal the next directional move.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.